ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR156/050/SRR15675950/SRR15675950_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR156/051/SRR15675951/SRR15675951_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR156/054/SRR15675954/SRR15675954_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR156/055/SRR15675955/SRR15675955_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR156/051/SRR15675951/SRR15675951_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR156/052/SRR15675952/SRR15675952_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR156/050/SRR15675950/SRR15675950_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR156/054/SRR15675954/SRR15675954_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR156/053/SRR15675953/SRR15675953_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR156/053/SRR15675953/SRR15675953_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR156/055/SRR15675955/SRR15675955_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR156/052/SRR15675952/SRR15675952_1.fastq.gzprimaryOK200GenomicsMacau Universityhttps://www.ebi.ac.uk/ena/browser/view/PRJNA759099To further investigate the therapeutic efficacy of modified-cyclodextrin and QT-NP against human atherosclerotic carotid plaque, the plaques were obtained from patients (n= 6) after carotid endarterectomy, and divided into two pieces of equal size . One of plaque piece was treated with 10 mM of modified-cyclodextrin and 0.5 mM of QT-NP for 24 h, and the other plaque piece was incubated with PBS as control group. The experimental results indicated that modified-cyclodextrin and QT-NP could also efficiently reduced atherosclerotic plaque in humans via cholesterol dissolution and anti-inflammation effect. In addition, transcriptome analysis on human atherosclerotic carotid tissue was conducted to confirm our experimental results.ENAHuman, human being, simple tissue., Man (Taxonomy), Homo sapiens, Modern Man, Modern, Tissue, man, Man, human, common carotid arterial subdivision, carotid artery, carotid, subdivision of common carotid arteryfalseHuman atherosclerotic carotid tissue sequencing2023-05-172021-09-03PRJNA759099